Dr. Trotter discusses necessary clinical considerations and practical use cases for the treatment of severe alopecia areata with treatments such as deuruxolitinib. She highlights the importance of systemic therapy in patients with severe alopecia areata due primarily to lack of spontaneous remission and risk of disease progression. Additionally, Dr. Trotter identifies best use cases for deuruxolitinib, emphasizes the importance of patient severity assessments such as the Alopecia Areata Scale, and suggests performing regular safety checks to continuously monitor concomitant conditions and inhibitors.
Podden och tillhörande omslagsbild på den här sidan tillhör
Matrix Medical Communications. Innehållet i podden är skapat av Matrix Medical Communications och inte av,
eller tillsammans med, Poddtoppen.
